sCD163 and sTARC are disease response biomarkers for Hodgkin's lymphoma

As published in Clinical Cancer Research, combined sCD163 and sTARC are better markers of disease response in patients with Hodgkin's lymphoma undergoing first-line therapy than either marker alone. sCD163 reflected tumor burden during treatment, while sTARC was more significant upon completion of therapy.

Read the article summary now:
http://www.mdlinx.com/oncology/news-article.cfm/4317702/?utm_source=in-house-msg&utm_medium=message&utm_campaign=reactiv-scott

sCD163 and sTARC are disease response biomarkers for Hodgkin Lymphoma

sCD163 and sTARC are disease response biomarkers for Hodgkin lymphoma

As published in Clinical Cancer Research, combined sCD163 and sTARC are better markers of disease response in patients with Hodgkin Lymphoma undergoing first-line therapy than either marker alone. sCD163 reflected tumor burden during treatment, while sTARC was more significant upon completion of therapy.

---------------------------------------------------------------------------------------------
The US Food and Drug Administration (FDA) has approved the expanded use of abiraterone acetate
( Zytiga, Janssen Biotech Inc) to first-line therapy for metastatic castration-resistant prostate cancer (mCRPC).
The drug, which decreases testosterone production, was approved in April 2011 as a second-line treatment after Docetaxel chemotherapy in the same population.
---------------------------------------------------------------------------------------------------

PET/CT Agent Identifies Aggressive Renal Cancers Noninvasively
Screening patients with renal masses with iodine-124-girentuximab had both a high specificity and sensitivity for identifying clear cell renal cell carcinoma, according to the results of a newly published open-label multicenter study.

(FROM CANCER NET)